Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Confo Therapeutics from Gent, company number BE0632474939, closed financial year 2025 with a result of € -17.4 million after tax. For that financial year Confo Therapeutics recorded revenue of € 176,727 and equity of € 33.3 million. Compared with financial year 2024, the result moved from € -11.3 million to € -17.4 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 33.3 million
▼ 34% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -17.4 million
▼ 54 % more loss than in 2024
Profit after tax over the fiscal year.
€ 6.2 million
▲ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -43.5 million.
People and assets in 2025
59
▲ 7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 7 million
▲ 17% vs 2024
€ 118,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 210,264
▼ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 150,880
▼ 38% vs 2024
€ 94,799 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 1.8 million
▲ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 47 days on average.
€ 1.5 million
▲ 55% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 500,000 | € 46,551,465 | € 1,274,528 | € 176,727 | ▼ 86% |
| Profit after taxes | € -15,585,554 | € 31,130,363 | € -11,335,378 | € -17,407,050 | ▼ € 6.1 million |
| Equity | € -7,560,505 | € 23,569,858 | € 50,633,033 | € 33,287,463 | ▼ 34% |
| Total debts | € 21,101,418 | € 20,387,156 | € 4,150,928 | € 4,483,091 | ▲ 8% |
| Cash | € 3,518,372 | € 6,928,270 | € 5,074,588 | € 6,156,119 | ▲ 21% |
| Retained profit | € -45,964,993 | € -14,834,630 | € -26,135,712 | € -43,481,282 | ▼ € 17.3 million |
| Bank debt | € 15,425,380 | € 15,335,492 | € 244,012 | € 150,880 | ▼ 38% |
| Balance sheet total | € 13,540,913 | € 43,957,014 | € 54,783,961 | € 37,770,554 | ▼ 31% |
| Employees (FTE) | 58.1 | 45.9 | 52 | 59 | ▲ 7 |
Key figures of Confo Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Confo Therapeutics?
What happened at Confo Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG stepped down as director. NBB
- Jeroen VANGINDERTAEL stepped down as director. NBB
- Caroline GODDEERIS stepped down as director. NBB
- Edward VAN WEZEL stepped down as director. NBB
- Cedric VERVERKEN stepped down as director. NBB
- Dieter WEINAND stepped down as director. NBB
- Robert SCOTT stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 17.4 million. Source: NBB ↗
In short
From € 15.6 million loss in 2022 to € 17.4 million loss in 2025.
Best year ever: 2023, with € 31.1 million profit.
Pays suppliers within 47 days on average.
A new publication or filing at Confo Therapeutics? We notify you, reason included.
Follow Confo TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by BGV3PoolCo 5 (13.7%), Fund+ NV (11.6%), Wellington Partners Life Sciences V GmbH & Co. KG (11.5%), Capricorn Health-Tech Fund NV (9.9%), V-Bio Fund 1 NV (8.9%) and AvH Growth Capital (7.3%).
Directors
According to the 2025 annual accounts
WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG
Director · represented by Varun GUPTA
since 2021 · until 2030
Jeroen VANGINDERTAEL
Director
since 2024 · until 2030
Caroline GODDEERIS
Director
since 2022 · until 2030
Dieter WEINAND
Director
since 2023 · until 2027
Edward VAN WEZEL
Director
since 2019 · until 2030
Robert SCOTT
Director
since 2020 · until 2027
Cedric VERVERKEN
Managing director
since 2016 · until 2030
Shareholders
13.7%
11.6%
Wellington Partners Life Sciences V GmbH & Co. KG
11.5%
8.9%
7.3%
5.9%
Perceptive Life Sciences Master Fund Ltd
3.8%
3.6%
2.9%
2.2%
1.9%
John BERRIMAN
0.6%
0.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 30
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Domain
Domain
confotherapeutics.com
Registered
2014-05-27
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2026-05-27
Website info
Features
Security
Network
Details
- Company number
- 0632.474.939
- VAT number
- BE 0632.474.939
- Registered office
- Technologiepark-Zwijnaarde 30, 9052 Gent
- Names & denominations
- Confo Therapeutics · Confo
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 11 June 2015
- Peppol
- Active · Active since 16 Jul 2025
- Contact
- confotherapeutics.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied